Evidence map›Paper›PMID 30530597›Full record

Trial reportAntimicrobial agents and chemotherapy2019

Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.

Erika Wallender, Nan Zhang, Melissa Conrad, Abel Kakuru, Mary Muhindo, Patrick Tumwebaze, Richard Kajubi, Daniel Mota, Jennifer Legac, Prasanna Jagannathan and 6 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Erika WallenderDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0003-1166-1587
Nan ZhangDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
Melissa ConradDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Abel KakuruInfectious Disease Research Collaboration, Kampala, Uganda.
Mary MuhindoInfectious Disease Research Collaboration, Kampala, Uganda.
Patrick TumwebazeInfectious Disease Research Collaboration, Kampala, Uganda.
Richard KajubiInfectious Disease Research Collaboration, Kampala, Uganda.
Daniel MotaDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Jennifer LegacDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Prasanna JagannathanDepartment of Medicine, Stanford University, Palo Alto, California, USA.ORCID 0000-0001-6305-758X
Diane HavlirDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Moses KamyaInfectious Disease Research Collaboration, Kampala, Uganda.
Grant DorseyDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Francesca AweekaDepartment of Clinical Pharmacy, University of California, San Francisco, San Francisco, California, USA.
Philip J RosenthalDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Rada M SavicDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA rada.savic@ucsf.edu.
University of California, San Francisco · USInfectious Diseases Research Collaboration · UGStanford University · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
The immunologic consequences of prenatal exposure to malariaP01HD059454 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2008 to 2017
$22.6M
CLINICAL, PHARMACOLOGY, DRUG ACTION &PHARMACOKINETICST32GM007546 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Radojka Savic · 1985 to 2026
$8.9M
Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in AfricaR01AI117001 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AWEEKA, FRANCESCA T., ROSENTHAL, PHILIP JON · 2015 to 2024
$7.1M
NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI117001NICHD NIH HHS P01 HD059454NIGMS NIH HHS T32 GM007546
6 · The paper itself

Abstract

Dihydroartemisinin-piperaquine (DHA-PQ) is under study for intermittent preventive treatment during pregnancy (IPTp), but it may accelerate selection for drug resistance. Understanding the relationships between piperaquine concentration, prevention of parasitemia, and selection for decreased drug sensitivity can inform control policies and optimization of DHA-PQ dosing. Piperaquine concentrations, measures of parasitemia, and

Indexed as

AntimalarialsArtemisininsDrug ResistanceDrug Therapy, CombinationFemaleHumansMalariaPiperazinesPregnancyPregnancy Complications, ParasiticQuinolinesUgandaYoung AdultAntimalarialsArtemisininsartenimolpiperaquinePiperazinesQuinolinesantimalarial resistancedihydroartemisinin-piperaquineintermittent preventive treatment during pregnancyPK/PD modeling

Identifiers

PMID30530597
PMCPMC6355581
OpenAlexW2903611377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.